T he brain renin-angiotensin system (RAS) plays a critical role in the development of neurogenic hypertension. Angiotensin (Ang) II, the main peptide in this system, increases sympathetic outflow and blood pressure (BP), while decreasing baroreflex gain and vagal tone, by acting on brain Ang II type 1 receptors (AT 1 R). In addition to this classic axis, compensatory mechanisms exist within the RAS. Angiotensin-converting enzyme type 2 (ACE2) was discovered almost 2 decades ago and has been established as a major component of the rescue mechanisms. ACE2 transforms Ang II into angiotensin-(1-7) [Ang-(1-7)], thus, turning the vasoconstrictor into a vasodilator peptide, promoting nitric oxide release, reducing sympathetic outflow, increasing baroreflex sensitivity, and ultimately reducing high BP. Our group previously reported that ACE2 is expressed throughout the brain, including in regions involved in central regulation of BP, such as the subfornical organ, paraventricular nucleus of hypothalamus, nucleus of the solitary tract, and rostral ventrolateral medulla.
experimental hypertension models, 5, 6 and ACE2 gene therapy can lead to reduced sympathetic drive and improved baroreflex sensitivity, contributing to a reduction of BP in those models. Despite these observations, the mechanisms leading to ACE2 downregulation in hypertension remain unknown.
ADAM17, a member of the a disintegrin and metalloproteases (ADAM) family, is known to cleave a variety of membrane-anchored proteins. 7 We previously demonstrated an ADAM17-mediated mechanism responsible for the impairment of ACE2 compensatory function in the mouse hypothalamus during neurogenic hypertension. 5 Accordingly, on brain RAS overactivation, ADAM17 is upregulated, leading to an increased ectodomain shedding of ACE2. As a result, the balance between classic and compensatory axes of the RAS is compromised, favoring the development of neurogenic hypertension. In our previous study, we first associated ADAM17-mediated shedding to the loss of membrane-bound ACE2 and increase in the shed form of ACE2 (sACE2). 5 However, there has been no study investigating the existence of this potentially deleterious mechanism in the central nervous system (CNS) of hypertensive patients or how it is regulated during hypertension development.
In this study, we investigated the correlation between ACE2 shedding and hypertension using cerebrospinal fluid (CSF) collected from normotensive and hypertensive patients. Because intracerebroventricular losartan blocked ADAM17 upregulation, 5 central AT 1 R were identified as critical players in ADAM17-mediated ACE2 shedding. However, AT 1 R are expressed on various cell types in the brain, including neurons, microglia, and astrocytes, which have been shown to contribute to neurogenic hypertension. [8] [9] [10] To further investigate the relationship between brain RAS and ADAM17 activation, we used the deoxycorticosterone acetate (DOCA)-salt model, which promotes RAS activation specifically in the brain to test the hypothesis that neuronal AT 1a R are essential for ADAM17-mediated ACE2 shedding in neurogenic hypertension. 5, 11 In patients, we observed an increase in sACE2, indicating increased ACE2 ectodomain shedding in hypertensive individuals. This rise in sACE2 was significantly correlated with elevated systolic BP and normalized by BP medications. Using transgenic mice with neuron-specific AT 1a R deficiency, our data provide strong evidence that neuronal AT 1a R are required for central ADAM17 upregulation during the development of DOCA-salt hypertension, in addition to its important roles in the regulation of sympathetic outflow and BP. Furthermore, we showed that signaling molecules downstream of AT 1a R, such as reactive oxygen species (ROS) and extracellular signal-regulated kinase (ERK),
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Novelty and Significance
What Is Known?
• Overactive brain renin-angiotensin system is associated with decreased angiotensin-converting enzyme 2 (ACE2) level and activity in the brain during the development of neurogenic hypertension.
• A disintegrin and metalloprotease 17 (ADAM17) is a member of the disintegrin and metalloproteinase family that has been shown to be upregulated in the brain in deoxycorticosterone acetate-salt-induced hypertensive mice.
What New Information Does This Article Contribute?
• Ectodomain shedding of ACE2 takes place in the human brain and is upregulated during hypertension, as indicated by increased ACE2 activity in cerebrospinal fluid samples from human patients.
• The increased cerebrospinal fluid tumor necrosis factor-α level in those hypertensive patients further supports that central ADAM17 levels are upregulated and are highly likely to mediate ACE2 shedding.
• Using a novel transgenic mouse model, which has angiotensin II type 1 receptor knocked down in brain neurons, we demonstrate that angiotensin II type 1 receptors promote ADAM17 upregulation selectively on neurons through increased expression and activity.
ACE2, an important link between classic renin-angiotensin system and its compensatory axis, is downregulated in various animal models of cardiovascular disease. In the deoxycorticosterone acetate-salt mouse neurogenic hypertension model, reduced ACE2 activity in the central nervous system is mediated through ADAM17. In this study, we provide evidence that ADAM17-mediated ACE2 shedding is also present in the human brain and is upregulated during the development of hypertension. Using a new transgenic mouse model, we show that neuronal cells play an important role in the development of neurogenic hypertension. Angiotensin II type 1 receptors promote ADAM17 upregulation selectively in neurons, through reactive oxygen species and the extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway. ADAM17-mediated ACE2 shedding is exacerbated in the brain of hypertensive patients and compromises the compensatory effect of angiotensin-(1-7).
play a critical part in mediating the AT 1a R-driven increase in ADAM17 activity in neurons.
Methods
A detailed Methods section is available in the Online Data Supplement. 
Patients' CSF Samples
Results
ACE2 Shedding Is Elevated in the Brain of Hypertensive Patients
We previously reported that neurogenic hypertension is associated with a reduction of ACE2 activity and an increase in ADAM17 activity in the mouse hypothalamus. 5 To address the relevance of ADAM17-mediated ACE2 shedding in humans and its potential link with neurogenic hypertension, sACE2 levels were assessed in the CSF of 27 patients (Online Table  II ), including 10 males (37±4 years) and 17 females (39±2 years). To first determine the assay's specificity, CSF samples from different patients were pooled together and incubated in the presence of increasing doses of recombinant human ACE2 and the ACE2 inhibitor MLN-4760. The data show a dose-dependent increase in Ang-(1-7) formation in this standard addition experiment, confirming assay specificity, as well as the efficiency of the antagonist to block the reaction ( Figure 1A ). To further validate the assay, random CSF samples were selected and pretreated with MLN-4760. Results show a dramatic reduction in their ability to form Ang-(1-7) from the spiked Ang II ( Figure 1B ), establishing sACE2 as the main enzyme converting Ang II into Ang-(1-7) in human CSF. When comparing the different patient groups, our data reveal that sACE2 activity was more than doubled in the CSF of individuals with uncontrolled hypertension (systolic BP, 159±7 mm Hg) compared with normotensive patients (systolic BP, 113±3 mm Hg; P<0.05; Figure 1C ). Patients with controlled BP (systolic BP, 125±4 mm Hg) exhibited a normalization of Figure 1 . Angiotensin-converting enzyme type 2 (ACE2) shedding is increased in the brain of hypertensive patients. Cerebrospinal fluid (CSF) was obtained from 27 patients and processed for ACE2 activity. Specificity of the assay was validated using an ACE2 inhibitor (MLN-4760) in pooled CSF samples (A), while randomly selected samples (B) reveal the predominance of ACE2 as the main enzyme converting angiotensin (Ang) II into Ang-(1-7) in humans CSF. Measurements of soluble ACE2 (sACE2) activity (C) and tumor necrosis factor-α (TNFα) levels (D) between normotensive patients (n=17), hypertensive with uncontrolled blood pressure (BP; n=7), and hypertensive with controlled BP (n=3) uncovered a 2-to 3-fold increase in both sACE2 activity and TNFα levels in uncontrolled hypertensive patients. BP medications significantly blunted sACE2 activity, while only a trend was noted for TNFα levels (1- sACE2 activity (P<0.05; Figure 1C ). Together, these data suggest that ADAM17-mediated ACE2 shedding is taking place in the CNS during human hypertension. To further confirm that the activity of ADAM17 is indeed increased in these patients, tumor necrosis factor-α (TNFα) levels were assessed. This cytokine showed exactly the same profile as sACE2, with a 2-fold increase in hypertension and a return to baseline in patients with controlled BP ( Figure 1D) . A significant positive correlation (P=0.012) was also established between sACE2 and systolic BP levels in these patients ( Figure 1E ).
Neuron-Targeted Deletion of AT 1a R Reduces DOCASalt-Induced Hypertension and Dysautonomia
In our previous study, intracerebroventricular losartan infusion in DOCA-salt-treated mice significantly attenuated both BP rise and increased ADAM17 expression, 5 indicating the pivotal role of AT 1a R in ADAM17 upregulation during RAS overactivity-related neurogenic hypertension. However, in the CNS, AT 1a R and ADAM17 are colocalized in various cell types that have all been shown to be involved in BP regulation. Therefore, we hypothesized that neuronal AT 1a R play a major role in the regulation of ADAM17 activity during DOCA-salt treatment and the ensuing development of neurogenic hypertension. To assess the contribution of neuronal AT 1a R, a new neuronal knockout mouse (AT1N) was generated, in which cre-recombinase expression is driven by the Nefh promoter ( Figure 2A and 2B). 12 Using primary neuron cultures, specific cre expression to neurons was verified by double-labeling with MAP2 ( Figure 2C ). Quantitative reverse transcription polymerase chain reaction performed with these cells confirmed a significant reduction of AT 1a R mRNA in AT1N mice compared with controls ( Figure 2D ), thus, validating the knockdown of AT 1a R in these mice neurons.
DOCA-salt, a well-accepted neurogenic hypertension model, 11 was previously reported by us to upregulate ADAM17 through RAS overactivation. 5 Before the DOCAsalt paradigm, BP and heart rate were not significantly different between AT1N mice and their control littermates, suggesting that neuronal AT 1a R are not involved in the maintenance of baseline BP and heart rate ( Figure 3A through 3C ). However, daily BP recording ( Figure 3A ) uncovered major differences between these 2 genotypes on DOCA-salt treatment. Indeed, while BP progressively increased in control littermates and rose by ≈30 mm Hg, it reached a plateau at a lower level in AT1N mice ( Figure 3A ). The BP traces difference started as early as the first day post-DOCA-salt and remained until the last day of treatment, where BP in AT1N This DOCA-salt-induced hypertension was blunted in AT 1a R knockout (AT1N) mice (n=10/group). B, Summary data for the MAP values before and after 18 days of DOCA-salt treatment. C, A plot for daily heart rate in which both control and AT1N mice were showing similar bradycardic response during DOCA-salt treatment. D, After 18 days of DOCA-salt treatment, spontaneous baroreceptor reflex sensitivity (SBRS) was calculated using the sequence method. E-H, Autonomic function was assessed pharmacologically by determining the changes in MAP (ΔMAP) and heart rate (ΔHeart Rate) after intraperitoneal injections of a β-blocker (E, propranolol, 4 mg/kg), a ganglionic blocker (F and H, chlorisondamine, 5 mg/kg), and a muscarinic antagonist (G, atropine, 1 mg/kg), n=6/group. I, Left ventricle (LV) mass in DOCA-salt or sham-treated control and AT1N mice (n=6/sham group and n=9/DOCA-salt-treated group), measured via echocardiography. J, Daily urinary norepinephrine excretion determined via ELISA (n=6 per group). Data are shown as the mean±SEM. Statistical significance: 2-way analysis of variance (ANOVA): *P<0.05, **P<0.01, ***P<0.001 vs respective shams; †P<0.05, † †P<0.01, † † †P<0.001 vs control+DOCA.
mice was significantly lower than in controls (21±3 versus 34±4 mm Hg; P<0.001; Figure 3B ). Interestingly, despite a smaller rise of BP in AT1N, the bradycardic response was similar between the 2 DOCA-salt-treated groups ( Figure 3C ), suggesting that baroreflex or autonomic function might be altered after AT 1a R knockdown. Indeed, the impaired baroreflex sensitivity induced by DOCA-salt was significantly attenuated in AT1N mice ( Figure 3D ). Analysis of autonomic function in control mice showed a typical increase in both cardiac ( Figure 3E ) and vascular ( Figure 3F ) sympathetic activities, as well as a reduction of vagal tone ( Figure 3G ), which contribute to the maintenance of hypertension in DOCA-salt-treated animals (*P<0.05 and **P<0.01 versus control). The similarity of intrinsic heart rate between groups, after ganglionic blockade ( Figure 3H ), suggests that these changes are related to autonomic function and not cardiac function. Deletion of AT 1a R was not associated with baseline changes in autonomic function. However, the dysautonomia observed in the control+DOCA group was prevented in AT1N mice as neither sympathetic drive nor vagal tone was altered after DOCA-salt treatment in these animals.
Control+DOCA mice exhibited an ≈50% left ventricular (LV) mass increase ( Figure 3I ), associated with early signs of heart failure, as evidenced by reduced ejection fraction and fractional shortening (Online Figure IA through IC) , and norepinephrine (NE) release, an index for sympathetic activity, was dramatically increased in these animals ( Figure 3J ). Interestingly, AT1N exhibited no sign of altered cardiac function while subjected to the DOCA-salt paradigm. Notably, LV mass was not increased ( Figure 3I ) despite identically increased fluid intake and urine output (Online Figure ID and IE), suggesting similar blood volumes between control and AT1N mice under DOCA-salt treatment. On the contrary, despite remaining elevated, NE excretion was reduced by >50% in AT1N treated with DOCA-salt ( Figure 3J ). Taken together, these data highlight the critical role of brain AT 1a R in promoting cardiac dysfunction through enhanced NE release in DOCA-salt hypertension.
Neuronal AT 1a R Are Required for ADAM17 Activation During DOCA-Salt Hypertension After DOCA-salt or sham treatment, the hypothalamus was collected to assess ADAM17 and ACE2 enzymatic activities. In control mice, ADAM17 activity was enhanced by ≈2-fold in the hypothalamus after DOCA-salt treatment (P<0.01 versus control sham; Figure 4A ). As a result, both ACE2 activity and expression were attenuated by ≈25% (P<0.05 versus control sham; Figure 4B and 4C), confirming the opposite relationship between ADAM17 and ACE2. AT 2 R gene expression was reduced as well in hypertensive animals ( Figure 4D ). Interestingly, AT 1a R deletion on neurons did not affect baseline ADAM17 activity and had no impact on ACE2 expression or activity in the brain, suggesting that AT 1a R do not regulate these enzymes in normal conditions. Surprisingly, in AT1N+DOCA mice, the enhanced ADAM17 activity, observed in control+DOCA animals, was totally blunted (Figure 4A ), leading to the preservation of ACE2 expression and activity, as well as AT 2 R gene expression ( Figure 4B through 4D) , in the hypothalamus of these mice. These data suggest that while constitutive ADAM17 enzymatic activity does not rely on the presence of neuronal AT 1a R, the DOCA-salt hypertension-mediated rise in its shedding activity requires AT 1a R expression in neurons. To determine the specificity of this mechanism, ADAM17 activity was also assessed in the heart and kidney. Interestingly, DOCA-salt treatment failed to alter total ADAM17 activity in the kidney ( Figure 4F ) but produced a significant increase in the cardiac LV, which was also prevented by AT 1a R knockdown in neurons ( Figure 4E ).
Hypertension Is Not Sufficient for ADAM17 Activation in the Brain
To further determine whether the lack of ADAM17 activation in AT1N mice is related to the absence of AT 1a R on neurons or the reduction of BP in these animals, we tested whether brain ADAM17 activation could result from an elevated BP, independently of RAS activation. Wild-type mice were infused with NE, a peripherally acting vasoconstrictor, at a dose previously reported to produce a sustained hypertension. 13 The 14-day infusion of NE drove significant cardiac and renal hypertrophy ( Figure 5A and 5B), supporting a BP increase after NE treatment in these mice. Unlike DOCA-salt treatment, compared with the saline-infused normotensive mice, there was no significant increase in ADAM17 activity in the hypothalamus of the NE-treated mice ( Figure 5C ). As a result, hypothalamic ACE2 activity in those mice remained intact after NE infusion ( Figure 5D ). These observations demonstrate that ADAM17 activation during DOCA-salt hypertension is mediated by neuronal AT 1a R rather than increased BP. Interestingly, ADAM17 activation was increased in the LV of NE-infused mice ( Figure 5E ), suggesting that NE leads to enhanced ADAM17 activity as a result of cardiac hypertrophy, as reported previously.
14 Together, these data indicate that neuronal AT 1a R play an essential role in the ADAM17-mediated ACE2 ectodomain shedding after brain RAS overactivation, ultimately contributing to the development of neurogenic hypertension.
Neuronal ADAM17 Is Selectively Upregulated by AT 1a R in DOCA-Salt Hypertension
To better understand the relationship between neuronal AT 1a R and ADAM17, a flow cytometry protocol was developed to sort different types of hypothalamic cells from DOCA-salttreated mice. After labeling with NeuN (neuronal nuclei)-conjugated Alexa Fluor 488 and GFAP (glial fibrillary acidic protein)-conjugated phycoerythrin antibodies, hypothalamic cells were sorted into neuronal, astrocyte, and non-neuronal/ nonastrocyte (NNNA) populations ( Figure 6A ). ADAM17 gene expression was easily detected among the various cell populations but only neuronal ADAM17 was upregulated after DOCA-salt treatment ( Figure 6B; P<0.05) . A trend to increased ADAM17 expression in NNNA population, however, did not reach statistical significance (P=0.19). At baseline, there was no difference in ADAM17 gene expression between control and AT1N mice, indicating again that ADAM17 expression in the CNS is not dependent on the presence of neuronal AT 1a R. Consistent with previous results showing a lack of increase in ADAM17 activity in AT1N+DOCA mice, the increased neuronal ADAM17 gene expression was prevented in these animals, and none of the other cell populations showed an increase in ADAM17 mRNA levels ( Figure 6B ). To confirm the fluorescence-activated cell sorting data, primary neurons cultured from control and AT1N mice were exposed to Ang II (100 nmol/L). After 2 hours, ADAM17 gene expression was significantly elevated by Ang II treatment in control mice (**P<0.01 versus control+vehicle) but not in AT1N (P=0.16; Figure 6C ). Interestingly, we observed that while neuronal TNFα mRNA was unaffected, it increased in control+DOCA mice in NNNA cells, and this was prevented in animals lacking neuronal AT 1a R ( Figure 6D ). These data suggest that although neurons are not the main source for TNFα, they might have the ability to regulate this cytokine expression on other cell types.
Oxidative Stress and ERK/Mitogen-Activated Protein Kinase Are Involved in AT 1a R-Mediated ADAM17 Activation
Because basal ADAM17 levels were not affected by neurontargeted AT 1a R knockdown, signals that upregulate ADAM17 during DOCA-salt treatment are thought to be downstream of AT 1a R activation. Among those, ERK/mitogen-activated protein kinase (MAPK) activation [15] [16] [17] and oxidative stress 18 have been shown to contribute to ADAM17 activation. In control mice, DOCA-salt treatment led to a 2-fold increase in phosphorylated ERK in the hypothalamus that was totally blunted in mice lacking neuronal AT 1a R ( Figure 7A and 7B). A rise in oxidative stress was also observed in control+DOCA mice, as evidenced by enhanced Nox4 protein expression in the hypothalamus ( Figure 7C ) and a dramatic increase in dihydroethidium (DHE) staining, an index of ROS production, in the paraventricular nucleus of hypothalamus ( Figure 7D and 7E). Importantly, neither Nox4 expression nor ROS production was affected by DOCA-salt treatment in AT1N mice ( Figure 7C through 7E) , confirming that these signaling molecules are regulated by AT 1a R in DOCA-salt hypertension. To confirm the involvement of ERK/MAPK and oxidative stress in neuronal ADAM17 activation, primary hypothalamic neurons were exposed to Ang II in the presence or absence of U0126, an MEK inhibitor (used to prevent ERK phosphorylation), SB203580 (a p38-MAPK inhibitor), and diphenyleneiodonium, an NADPH oxidase inhibitor. As shown by us previously in neuronal cell lines, 18 ADAM17 activity was significantly upregulated by Ang II treatment ( Figure 7F ), and this effect was completely blocked by pretreatment with U0126, SB203580, or diphenyleneiodonium. Taken together, our data provide strong evidence that neuronal AT 1a R mediate ADAM17 activation through its ERK/MAPK and oxidative stress downstream signals, which are also known to be upregulated during RAS overactivation.
Discussion
Although ADAM17 (aka TNFα convertase) was originally discovered as a key sheddase in the formation of cytokines, such as TNFα, its wide spectrum of substrates 19 also highlights its important role, beyond inflammation, in the CNS and cardiovascular system. 7 An opposite relationship between ADAM17 and ACE2, a pivotal member of the compensatory RAS, was discovered by the observation of increased sACE2 levels in the culture medium of cells transfected with ADAM17. 20 ACE2 is a cell surface-bound enzyme, with its catalytic site exposed to the extracellular surface 21 ; therefore, ADAM17-mediated ectodomain shedding might compromise the RAS compensatory axis by impairing ACE2 enzymatic activity or its ability to process Ang II on the cell surface. By demonstrating this Figure 5 . Norepinephrine (NE)-induced hypertension does not induce a disintegrin and metalloprotease 17 (ADAM17) activation or affect angiotensin-converting enzyme type 2 (ACE2) activity in the hypothalamus. Both heart weight (A) and kidney weight (B) were significantly increased after 2 weeks of subcutaneous NE infusion (3.8 μg/kg per min), indicating cardiac and renal hypertrophy. ADAM17 (C) and ACE2 (D) activity assays were performed using hypothalami samples isolated from NE-or saline-treated wild-type (WT) mice. ADAM17 activity (E) was elevated in the left ventricle (LV) after NE infusion (n=5-6/group). Data are shown as mean±SEM. Student's t test: *P<0.05 vs WT+saline.
opposite relationship in the hypothalamus, our previous study was first to point out the contributory role of ADAM17 in the development of neurogenic hypertension. 5 However, in the absence of data in humans, the relevance and potential therapeutic implications of this process in the CNS remained unknown.
Despite the numerous peptidases involved in the formation of Ang-(1-7), 22 our data suggest that ACE2 seems to be the main enzyme hydrolyzing Ang II into Ang-(1-7) in human CSF ( Figure 1B) ; therefore, preservation of ACE2 enzymatic activity is critical to the compensatory RAS in the CNS. Among the mechanisms leading to impaired ACE2 activity in hypertension, we previously reported ADAM17-mediated shedding and AT 1 R-dependent internalization. 5, 6 While there are no data available for the latter, in humans, elevated sACE2 has been reported in the periphery in heart failure, 23, 24 hypertension, 24 severe acute respiratory syndrome, 25 and type 1 diabetes mellitus. 26 Here, we provide evidence of increased sACE2 in CSF, correlated with elevated systolic BP, in hypertensive patients. Despite a lack of direct evidence, the similarity between sACE2 and TNFα profiles ( Figure 1C and   1D ) in the CSF of these patients points to ADAM17-mediated shedding. In addition, the normalization of sACE2 levels in patients with controlled BP also supports the link between overactive RAS, enhanced ADAM17 activity, and elevated sympathetic drive because these individuals were taking a RAS blocker or a sympatholytic (Online Table II ) in combination with a diuretic or calcium-channel blocker. Therefore, it is conceivable that these drugs might have directly or indirectly reduced brain RAS activity, thwarting ADAM17 activation, and ultimately contributed to the preservation of ACE2 on the cell surface. This hypothesis is based on the assumption that sACE2 is less efficient at converting Ang II into Ang-(1-7) than the membrane-bound enzyme. This reduction in enzymatic efficiency might be because of decreased local metabolism or changed structure. Whether sACE2 has therapeutic benefits or is merely a degradation product resulting from RAS overactivation remains controversial.
To further clarify the mechanisms involved in ADAM17-mediated ACE2 shedding, we took advantage of the DOCAsalt hypertension model, which was reported to have a strong neurogenic component and typical features, including salt sensitivity, low plasma renin levels, and an overactive brain RAS. 11 As the main mediator of brain RAS overactivity, the AT 1a R was previously demonstrated to prompt ADAM17 upregulation both in vitro 18 and in vivo. 5 Moreover, in recent years, cell-specific expression of AT 1a R, in the CNS, has been shown to contribute to neurogenic hypertension 10, 27, 28 and other ailments. 29 Because AT 1a R and ADAM17 coexist on various cell types, including endothelial cells, 30 vascular smooth muscle cells, 31 glial cells, and neurons, 32 the contribution of cell-specific ADAM17 activation to the development of hypertension must be determined to insure selective targeting. To address the contribution of neuronal AT 1a R to ADAM17 activation, we generated a cell-specific knockout mouse by taking advantage of the neuron-specific Nefh promoter. Nefh is expressed throughout the brain, including in the hypothalamus, pons, and medulla, which contain the majority of nuclei involved in BP regulation.
12 Accordingly, most of AT 1a R neuronal expression is thought to be knocked down in AT1N mice.
To the best of our knowledge, this study provides the first evidence that ADAM17 activation in the CNS, as a result of DOCA-salt treatment, is entirely dependent on neuronal AT 1a R ( Figure 5A ). In addition, it is not secondary to hypertension because NE infusion, by which BP can be increased to ≈160 mm Hg, 13 failed to increase the sheddase activity in the brain ( Figure 5C ), while it did promote activation in the heart, as reported previously.
14 Importantly, this new mechanism is dependent on brain RAS overactivation because AT 1a R deletion did not alter baseline ADAM17 activity, and it is restricted to neurons. In vitro studies have shown that caveolin-1, a membrane lipid raft marker, coimmunoprecipitates with AT 1 R on agonist stimulation, and these rafts play a critical role for AT 1 R-mediated signal transduction. 33, 34 Altogether, it is conceivable that on RAS overactivation, AT 1a R could move to a closer location from which its downstream signals can affect ADAM17 in a more efficient way.
On acute stimulation, intracellular signals resulting from GPCR (G-protein-coupled receptor) activation or oxidative stress can activate ADAM17 within a few minutes via phosphorylation of its cytoplasmic domain 17 or upregulate ADAM17 availability through increasing its translocation. In addition to its critical role in the migration of AT 1a R into membrane microdomains, 35 ROS are actually important to Golgi apparatus-mediated ADAM17 transport, which requires p47 phox . 36 In chronic states, such as DOCA-salt treatment, the expression of ADAM17 could be upregulated through the activation of transcription factors, such as CREB (cAMP response element-binding protein) and NFκB (nuclear factor-κB), which are downstream targets of ROS/ERK/MAPK-mediated signaling pathways, as confirmed by our data ( Figure 7F) .
Besides the brain, ADAM17 is also expressed in end organs of neurogenic hypertension, including heart and kidneys. In the heart, systemic Ang II infusion increases ADAM17 activity and ADAM17-mediated ACE2 shedding in mouse LV, accompanied with upregulated cardiac hypertrophy, which can be blocked by deletion of ADAM17 independently of decreasing BP. 14, 36 In the kidney, ADAM17-mediated ACE2 downregulation has also been found to be altered in mouse and human renal diseases. 37, 38 In this study, we observed an upregulation of ADAM17 activity in the mouse heart after DOCA-salt treatment presumably driven by increased NE level during hypertension (Figures 4 and 5) . Although we did not see any significant change in overall renal ADAM17 activity, ACE2 shedding from tubular and glomerular epithelial cells may still play a role in the alteration of renal function during DOCA-salt treatment.
While our data certainly highlight an essential role for neurons and position them upstream among the various contributors to ADAM17-mediated neurogenic hypertension, consideration should be given to other CNS cells, as all showed robust levels of ADAM17 mRNA. With regards to astrocytes, despite recent data suggesting a contribution to Ang IImediated sympathetic outflow, 28 the lack of detectable AT 1a R mRNA ( Figure 6E ) and failure of DOCA-salt to increase ADAM17 gene expression in these cells suggest that their role might be merely limited to the synthesis of angiotensinogen ( Figure 6B ). The situation is less clear for other cell types because of fluorescence-activated cell sorting resolution. The NNNA population which includes mostly microglia and vascular cells also showed a significant level of ADAM17 mRNA and a trend to upregulation on DOCA-salt treatment. Although AT 1a R gene expression was undetectable in these cells, likely because of its overabundance in neurons, the rise of TNFα, and maybe ADAM17, mRNA after DOCA-salt treatment highlights a partnership between neuronal AT 1a R and these cells. The contribution of ADAM17 in the CNS to hypertension is not necessarily identical between cells and likely depends on its substrates and their location. In vascular smooth muscle cell, ADAM17-mediated HB-EGF (heparin-binding epidermal growth factor) upregulation is one of the mechanism of vascular remodeling, 39 which may contribute to the pathological process in late-stage hypertension and increase the possibility of cerebrovascular accidents. ADAM17 is also the major source of soluble (ie, active) TNFα in vascular and glial cells; therefore, in DOCA-salt hypertension, the sheddase is poised to play a key role in the process of neuroinflammation, most likely from microglia, 40 which can be activated by Ang II and infiltrating immune cells. 41 The cell specificity of ADAM17 is further confirmed by the lack of TNFα mRNA upregulation in neurons after DOCA-salt treatment, while there was almost a 2-fold increase in NNNA cells. Interestingly, the rise of TNFα mRNA in NNNA cells was blunted in mice lacking neuronal AT 1a R and treated with DOCA-salt ( Figure 6D ). These data clearly suggest a cross talk between neurons and these other cells. Microparticles, capable of carrying mRNA as well as receptors, can be formed by Ang II and induce membrane trafficking in hypothalamic cells. 42, 43 Although not the focus of this study, their involvement could be an attractive hypothesis to explain AT 1a R-ADAM17 cooperation between neurons and TNFα-producing cells in hypertension.
Limitations
Though we provide strong evidence that AT 1 R promote ADAM17-mediated ACE2 shedding in the development of neurogenic hypertension, there are some limitations in our study about the experimental methods we chose. (1) While diphenyleneiodonium is wildly used as an inhibitor of flavoenzymes and often accepted as evidence of NADPH oxidase inhibition, it is a nonspecific inhibitor that binds strongly to flavoproteins, including nitric oxide synthase, NADPHubiquinone oxidoreductase, NADPH oxidases, and NADPH cytochrome P450 oxidoreductase. 44, 45 It is well documented that Ang II-associated ROS production is not limited to NADPH oxidase 46 ; therefore, using diphenyleneiodonium is an effective choice to block more sources of ROS, but on the other hand, the lack of specificity prevented from a clear identification of the signaling molecules involved in the regulation of ADAM17 activity, during Ang II treatment.
(2) In this study, we used DHE staining to detect DOCAsalt-induced ROS production in the paraventricular nucleus Figure 7 . Angiotensin II type 1 receptors (AT 1a R) downstream signaling mediates neuronal a disintegrin and metalloprotease 17 (ADAM17) activation. A, Representative Western blot for phosphorylated extracellular signal-regulated kinase (p-ERK) and Nox4 in 2 to 3 independent hypothalamus homogenates per group. Summary of p-ERK (B) and Nox4 (C) Western blot data based on densitometric analysis (n=5/group). D, Representative results for dihydroethidium (DHE) staining in the paraventricular nucleus of hypothalamus (PVN) region of deoxycorticosterone acetate (DOCA)-salt-or sham-treated mice. E, Quantitative results for the DHE staining (n=4/group). F, ADAM17 activity assay performed in cultured primary hypothalamic neurons isolated from wild-type neonates. The cultured neurons were treated with angiotensin (Ang) II (300 nmol/L, 18 hour), 1 hour after pretreatment with diphenyleneiodonium (DPI, a flavoenzymes inhibitor, 10 μM), U0126 (MEK inhibitor, used to block ERK phosphorylation, 10 μM), SB203580 (a p38MAPK blocker, 10 μM), and DPI+U0126, respectively, for 18 h (n=4-6 independent cultures/group). of hypothalamus. Because of its ability to passively diffuse into cells and its high reactivity, DHE has been used to detect cytosolic superoxide. However, there are other products generated by DHE. Apart from superoxide-mediated oxidation to 2-hydroxyethidium, DHE can also undergo unspecific oxidation via ONOO − or • OH into ethidium. 47 Because the difference in their fluorescence spectra is small, analytical methods, like high-performance liquid chromatography and mass spectrometry, should be applied to verify the specific superoxide signals. 48 Electron paramagnetic resonance spectroscopy can also be used for ROS detection. 49 ( 3) The present data highlight significant variability within our ADAM17 activity assay, so it is not suitable for comparisons between experiments. When using this method, it is imperative to include all experimental groups on the same assay and apply positive (ADAM17-overexpressing cell lysate) and negative (lysis buffer) controls to validate its efficiency. (4) In the DOCA-salt hypertensive mice, we saw significant hypertrophy in heart and kidney, both of which are important organs in the development of hypertension, and we assessed ADAM17 in these tissues. Although Salem et al 50 previously reported that renal ADAM17 expression was increased in whole kidney lysates, highlighting that total renal ADAM17 could be changed during the pathological process, it is more informative to perform such assays in dissected tissues or regions (eg, cortex versus medulla) as these tissues/regions contain multiple cell types with often opposite roles.
In summary, the present study describes a novel mechanism taking place in the CNS of hypertensive patients, by which ADAM17 cleaves ACE2 from the cell surface, potentially leading to the loss of compensatory activity and contributing to neurogenic hypertension. Neuronal AT 1a R were further shown to be required for this process and for the formation of TNFα from other cells. We postulate that an important role for neuronal ADAM17-mediated ectodomain shedding is to unbalance the relationship between the classic RAS and its compensatory axis, thus, increasing sympathetic activity in neurogenic hypertension.
